ADC Name	SGN-CD47M
Synonyms	SGN-CD47M; SGN CD47M; SGNCD47M    Click to Show/Hide
Organization	Seagen Inc.
Drug Status	Phase 1 (discontinued)
Antibody Name	Humanized anti-CD47 IgG1 mAb					Antibody Info
Antigen Name	Leukocyte surface antigen CD47 (CD47)					Antigen Info
Payload Name	Monomethyl auristatin E					Payload Info
Payload Target	Microtubule (MT)					Target Info
Linker Name	Metalloproteinases cleavable linker					Linker Info

Standard Type	Value	Units	Description	Reference
Maximum Observed Concentration (Cmax)	322	ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.	[1]
Area Under the Concentration-Time Curve (AUC)	600	day·ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1, AUC0-21day.	[1]
Maximum Observed Concentration (Cmax)	475	ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.	[1]
Area Under the Concentration-Time Curve (AUC)	1279	day·ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1, AUC0-21day.	[1]
Maximum Observed Concentration (Cmax)	707	ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.	[1]
Area Under the Concentration-Time Curve (AUC)	1751	day·ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2, AUC0-21day.	[1]
Maximum Observed Concentration (Cmax)	591	ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.	[1]
Area Under the Concentration-Time Curve (AUC)	1515	day·ug/mL	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean, AUC0-21day.	[1]

Standard Type	Value	Units	Description	Reference
Volume of Distribution (Vd)	40	mL/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.	[1]
Volume of Distribution (Vd)	40	mL/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.	[1]
Volume of Distribution (Vd)	29	mL/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.	[1]
Volume of Distribution (Vd)	35	mL/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.	[1]

Standard Type	Value	Units	Description	Reference
Elimination Half-Life (t1/2)	2	day	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.	[1]
Clearance (CL)	17	mL/day/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 10 mg/kg, Subject 1.	[1]
Elimination Half-Life (t1/2)	2.1	day	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.	[1]
Clearance (CL)	15	mL/day/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 1.	[1]
Elimination Half-Life (t1/2)	1.3	day	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.	[1]
Clearance (CL)	11	mL/day/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, Subject 2.	[1]
Elimination Half-Life (t1/2)	1.7	day	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.	[1]
Clearance (CL)	13	mL/day/kg	Pharmacokinetic parameters of ADC in monkey plasma following a single IV dose of ADC 20 mg/kg, mean.	[1]

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Undisclosed	NCT03957096	PHASE1	A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors

Experiment 1 Reporting the Activity Date of This ADC					[2]
Patients Enrolled	Eligible patients (ECOG 0-1) must have specified metastatic solid tumors and measurable disease, with adequate contraception required. Key exclusions include prior CD47/SIRPalpha therapy, active CNS metastases, HIV/hepatitis infections, recent transfusions or immunosuppression, and cardiovascular events within 6 months. Life expectancy must exceed 12 weeks.    Click to Show/Hide
Administration Dosage	.
Related Clinical Trial
NCT Number	NCT03957096	Clinical Status	PHASE1
Clinical Description	A Phase 1 Study of SGN-CD47M in Patients With Advanced Solid Tumors
Primary Endpoint	The study will assess safety parameters including adverse events and laboratory abnormalities over 24 months, with dose-limiting toxicities evaluated specifically within the first 28 days of treatment.
Other Endpoint	Efficacy evaluations will include ORR, DOR, PFS and OS according to both RECIST v1.1 and iRECIST criteria, with assessments continuing for up to 4 years. Pharmacokinetic measurements (AUC, Cmax, Tmax, Ctrough) and immunogenicity (ADA) will be monitored for 24 months.

Ref 1	Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Ref 2	A Safety Study of SGN-CD47M in Patients With Solid Tumors